Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

hydromorphone hydrochloride injection, USP (HIGH POTENCY) Principal Display Panel

PRINCIPAL DISPLAY PANEL - 1 mL Vial Label

1 mL Single-dose Vial
NDC 0409-2634-10

HIGH POTENCY FORMULATION

Hydromorphone
Hydrochloride Injection
CII

10 mg/mL

Rx only

Distributed by Hospira, Inc.,
Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 1 mL Vial Label

PRINCIPAL DISPLAY PANEL - 1 mL Vial Box

10 x 1 mL Single-dose Vials
Rx only

NDC 0409-2634-01
Contains 10 of NDC 0409-2634-10

HIGH POTENCY FORMULATION
Hydromorphone
Hydrochloride Injection
CII

10 mg/mL

Hospira

PRINCIPAL DISPLAY PANEL - 1 mL Vial Box

PRINCIPAL DISPLAY PANEL - 5 mL Vial Label

5 mL Single-dose Vial
NDC 0409-2634-25

HIGH POTENCY FORMULATION

Hydromorphone
Hydrochloride Injection
CII

50 mg/5 mL
(10 mg/mL)

Rx only

FOR USE IN THE PREPARATION OF
LARGE-VOLUME PARENTERAL
SOLUTIONS

Distributed by Hospira, Inc., Lake Forest, IL 60045 USA

PRINCIPAL DISPLAY PANEL - 5 mL Vial Label

PRINCIPAL DISPLAY PANEL - 5 mL Vial Box

10 x 5 mL Single-dose Vials

Rx only

NDC 0409-2634-05
Contains 10 of NDC 0409-2634-25

HIGH POTENCY FORMULATION

Hydromorphone
Hydrochloride Injection
CII

50 mg/5 mL (10 mg/mL)

FOR USE IN THE PREPARATION OF LARGE-VOLUME PARENTERAL SOLUTIONS

Hospira

PRINCIPAL DISPLAY PANEL - 5 mL Vial Box

PRINCIPAL DISPLAY PANEL - 50 mL Vial Label

NDC-0409-2634-50

50 mL Single-dose Vial

HIGH POTENCY FORMULATION

Hydromorphone
Hydrochloride Injection

CII

Rx only

500 mg/50 mL (10 mg/mL)

SINGLE-DOSE CONTAINER FOR USE IN THE PREPARATION OF LARGE-
VOLUME PARENTERAL SOLUTIONS.

Hospira, Inc., Lake Forest, IL 60045 USA
Printed in USA

Hospira

PRINCIPAL DISPLAY PANEL - 50 mL Vial Label

PRINCIPAL DISPLAY PANEL - 50 mL Vial Box

NDC 0409-2634-50

1 x 50 mL Single-dose Vial
Rx only

HIGH POTENCY FORMULATION

Hydromorphone
Hydrochloride
Injection

CII

500 mg/50 mL (10 mg/mL)

FOR USE
IN THE PREPARATION
OF LARGE-VOLUME
PARENTERAL
SOLUTIONS

RETAIN IN THE CARTON
UNTIL TIME OF USE.

Hospira

PRINCIPAL DISPLAY PANEL - 50 mL Vial Box
Show All Hide All
Show All Hide All
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Contact Medical Information.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event
Pfizer Safety

To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site

*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.

If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.

FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatchor by calling
(800)-332-1088.